FreeStyle Blood Glucose Monitoring (BGM) Systems
Portable blood glucose meters with insulin dose tracking
Device · EmbeddedCompany source
Company profile
About Abbott Diabetes Care
Abbott Diabetes Care develops FreeStyle Libre, a world-leading continuous glucose monitoring (CGM) portfolio for diabetes management with advanced analytics and innovation.
Company description Abbott Diabetes Care official website
Mission. Progress is our purpose. With our world-leading FreeStyle Libre portfolio, Abbott remains committed to advancing diabetes technology. Through ongoing innovation and research, we're driving progress that powers better care worldwide.
Primary marketChronic Disease Management & Digital Therapeutics
Commercial modelCommercial information available on request
Company presenceOfficial website
Work at Abbott Diabetes Care?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- Diabetes management
- Type 1 diabetes
- Type 2 diabetes
Who it serves
- Caregivers
- Health systems
- Healthcare professionals
- Patients with diabetes
Deployment & integration
Cloud Saas · Embedded deployment with recorded integration context.
Recorded integration context: Digital health platforms, LibreLinkUp app, mylife CamAPS FX app, mylife Loop automated insulin delivery system, mylife YpsoPump insulin pump, Omnipod 5 Automated Insulin Delivery System, Smart insulin pens.
Geographic context
MarketsEurope · Global · United States · Worldwide (7 million users)
Company sourceOfficial website
Company milestones
Platform expansion
FreeStyle Libre 3 system launched with best-in-class connectivity and world's smallest sensor. FreeStyle Libre 3 Plus and Libre 2 Plus sensors authorized for automated insulin delivery system integration. New Libre app introduced with enhanced alerts and silent mode.
Partnerships
Recorded partners
- Digital health platforms
- mylife (Ypsomed)
- Omnipod (Insulet)
- Smart insulin pen manufacturers
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
FreeStyle Libre 2 System
Proven CGM system with optional real-time alarms and 15-day wear
Device · EmbeddedCompany source
FreeStyle Libre 3 System
World's smallest, thinnest CGM sensor with minute-by-minute glucose monitoring
Device · EmbeddedCompany source
FreeStyle Libre Select System
15-day wear CGM with water resistance for active lifestyles
Device · EmbeddedCompany source
FreeStyle Libre System (Original)
No finger pricks CGM with 1-second scan and 14-day wear
Device · EmbeddedCompany source
FreeStyleLibreLink App
Mobile app for scanning and viewing FreeStyle Libre sensor data
Software · Cloud SaaSCompany source
Libre App
Enhanced mobile app for FreeStyle Libre sensors with automatic glucose updates
Software · Cloud SaaSCompany source
LibreLinkUp App
Remote glucose monitoring app for caregivers and loved ones
Software · Cloud SaaSCompany source
LibreView
Cloud-based diabetes management platform for patients and healthcare providers
Platform · Cloud SaaSCompany source
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
Effectiveness of Continuous Glucose Monitoring in Non-Intensively Managed Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Journal of diabetes science and technology · Oct 14, 2026
Exploring Diabetes Management Behaviors with FreeStyle Libre 2: Insights from Adults with Type 2 Diabetes in Quebec.Canadian journal of diabetes · Sep 30, 2026
Association Between Continuous Glucose Monitoring Utilization and Glucagon-Like Peptide-1 Receptor Agonist Discontinuation in Type 2 Diabetes: A Real-World Study.Diabetes technology & therapeutics · Sep 19, 2026
Updated glucose management indicator (GMI) better aligns with HbA1c than current GMI: implications for clinical practice and reporting.Diabetologia · Aug 1, 2026
Accuracy of a 15-day Factory-Calibrated Continuous Glucose Monitoring System With Improved Sensor Design.Journal of diabetes science and technology · Jul 1, 2026
IBOA and MBPA are not present in FreeStyle Libre.Actas dermo-sifiliograficas · Jun 24, 2026
Clinical validation
Clinical-trial records
No linked records are currently available.
Regulatory
Regulatory records
No linked records are currently available.
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
A1c reduction
Proven to lower A1c over time with FreeStyle Libre 3 system
Hypoglycemia reduction
Proven to reduce hypos with FreeStyle Libre 2 and 3 systems
Patient understanding
95% of patients report better understanding of glucose fluctuations
User confidence
Helping people manage diabetes with more confidence
Clinical study population
Reduction in hypoglycemic events and A1c improvement using FreeStyle Libre systems
Proven to lower A1c and reduce hypoglycemic events over time
Global patient population
Continuous glucose monitoring for diabetes management across 7 million users worldwide
Trusted by 7 million users worldwide; 95% of patients report better understanding of glucose fluctuations
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
No active leadership profiles are currently listed.
06 · Company updates
Updates from Abbott Diabetes Care
Recent articles published on Abbott Diabetes Care's official website.
No Company updates are currently listed.
07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Chronic Disease Management & Digital Therapeutics
Companies using AI and digital health tools to help patients manage chronic conditions through digital therapeutics, gamified health management, and AI-powered coaching. Covers management of all chronic diseases including diabetes, hypertension, COPD, heart disease, and multi-condition platforms. Includes continuous glucose monitoring (CGM) systems with AI analytics and insulin optimization algorithms.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.